Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.